Organization
Samsung Medical Center
43 clinical trials
78 abstracts
4 posters
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).Org: Asan Medical Center, University of California Los Angeles, University of California Irvine, Hannover Medical School, Zhongshan Hospital,
Abstract
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).Org: Humanity and Health Clinical Trial Center, Liver Unit and HPB Oncology Area, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Barcelona Clinic Liver Cancer,
Abstract
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.Org: National Cancer Center Hospital Japan East, St. Marianna University School of Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Seoul National University College of Medicine, HonorHealth Research Institute,
Abstract
Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.Org: Gregorio Marañón University General Hospital, IRCCS Istituto Romagnolo per lo Studio dei Tumori, Institute of Oncology Ljubljana, Roche Products Limited, Roche,
Abstract
Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).Org: Sun Yat-sen University Cancer Center (China), Rui Jin Hospital Affiliated to Shanghai Jiao Tong University, Jinagsu Province Institute of Cancer Research, The University of Texas MD Anderson Cancer Center, Chongqing University Cancer Hospital,
Abstract
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Sackler School of Medicine, Hospital Universitario Fundación Jiménez Díaz, McGill University and MUHC, Sungkyunkwan University School of Medicine, Hospital Germans Trias i Pujol,
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.Org: Memorial Sloan Kettering Cancer Center, Kanagawa Cancer Center, Severance Hospital, Hospital Clinic de Barcelona, Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.Org: Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Gangnam Severance Hospital, Seoul St. Mary's Hospital,
Abstract
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.Org: START Midwest, Grand Rapids, MI, Memorial Sloan Kettering Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Yale School of Medicine, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,
Abstract
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).Org: Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Medical University of Lodz, Samodzielny Publiczny Szpital Kliniczny,
Abstract
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.Org: St. Vincent’s Hospital, The Catholic University of Korea, Haematology Unit, Royal Adelaide Hospital, Sungkyunkwan University School of Medicine,
Abstract
Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study.Org: Sarah Cannon Research Institute/Tennessee Oncology, Asan Medical Center, Samsung Medical Center, Menarini Group, Hospital Universitario 12 de Octubre,
Abstract
Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06).Org: Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Dongtan Sacred Heart Hospital, Hallym University, Division of Breast Surgery, Samsung Medical Center,
Abstract
Radiogenomics of homologous recombination deficiency (HRD) in breast cancer: Radiomics-based image biomarker for HRD.Org: Genome Insight Inc., Bucheon St. Mary's Hospital, Samsung Medical Center, Genome Insight, Inc., Sungkyunkwan University School of Medicine,
Abstract
Patient-reported outcomes in N1 breast cancer: A phase III trial comparing whole-breast to whole-breast plus regional irradiation after taxane-based chemotherapy (KROG 1701).Org: Samsung Medical Center, Chonnam National University Medical School and CNU Hwasun Hospital, Asan Medical Center, Soonchunhyang University Hospital, Gil Medical Center,
Abstract
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy,
Abstract
Continuous remote monitoring of performance status in patients with NSCLC through fitness tracker–derived life-log data.Org: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Samsung Medical Center, Sungkyunkwan University School of Medicine, AI Graduate School,
Clinical trial
Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction: A Multicenter Randomized Noninferiority TrialStatus: Recruiting, Estimated PCD: 2025-10-30
Abstract
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.Org: AstraZeneca, Winship Cancer Institute, Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa Cancer Center, Cancer Center Clínica Universidad de Navarra, Madrid, Spain,
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,
Abstract
Identification of HER2 ultra-low based on an artificial intelligence (AI)-powered HER2 subcellular quantification from HER2 immunohistochemistry images.Org: Lunit Inc., Department of Pathology, Samsung Medical Center, Department of Pathology, Kyung Hee University Hospital, Digital Medicine Society (DiMe), Samsung Medical Center,
Clinical trial
An Open Label, Phase 2 Basket Study of Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 FusionStatus: Not yet recruiting, Estimated PCD: 2027-04-30
Clinical trial
Effect of Remimazolam Versus Propofol Anesthesia on Postoperative Delirium in Neurosurgical Patients: A Randomised, Controlled, Noninferiority TrialStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
The Efficacy of Enavogliflozin on Exercise Performance and Diastolic Function in Heart Failure With Preserved Ejection Fraction: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Abstract
A phase 1 study to evaluate the safety and preliminary efficacy of minnelide given alone or in combination with paclitaxel in advanced gastric cancer.Org: Minneamrita Therapeutics, Samsung Medical Center, University of Miami School of Medicine, Sungkyunkwan University School of Medicine,
Abstract
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.Org: Samsung Medical Center, Seoul National University Hospital, South Korea,
Abstract
Comparison of machine learning algorithms for the radiomic classification of gastric subepithelial tumors.Org: Samsung Medical Center, Seoul National University Hospital, South Korea,
Abstract
Deep learning–based chest CT model to predict treatment response to immune checkpoint inhibitors in non-small cell lung cancer independently and additively to histopathological biomarkers.Org: Oncology Therapeutic Development, Lunit Inc., Seoul National University Hospital, South Korea, Samsung Medical Center,
Abstract
A phase II study of nivolumab in patients with recurrent or metastatic carcinosarcomas.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Hospital, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, Samsung Medical Center,
Clinical trial
Clinical Assessment on the Safety and Potential Efficacy of Mesenchymal Stem Cells Preconditioned With Ethionamide (ET-STEM) in Patients With Frontotemporal Dementia (FTD)Status: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
Phase II Study of Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx)(HER2 Negative ARM) or Pembrolizumab + Trastuzumab+ Capecitabine／Cisplatin (HER2 Positive ARM) in Metastatic GC as First-line TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-02-06
Abstract
A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine,
Clinical trial
The Effect of Usual Dose Rosuvastatin Plue Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque: A Randomized Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2027-01-28
Clinical trial
SMart Angioplasty Research Team: Comparison Between P2Y12 Inhibitor MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary BiorEsorbable Scaffold II: (SMART-CHOICE II) TrialStatus: Terminated, Estimated PCD: 2017-12-18
Clinical trial
A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like SyndromeStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Comparison of Polymer-Free Cobalt-Chromium Thin Drug-Coated Stents With Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy With Conventional 12-Month Dual Antiplatelet TherapyStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder ContractilityStatus: Completed, Estimated PCD: 2008-08-01
Clinical trial
Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCIStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Genetic and Histopathologic Characteristics of Interstitial CystitisStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive Non-small Cell Lung Cancer Patients With Asymptomatic Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Lazertinib and Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment: A Phase II Multi-center TrialStatus: Not yet recruiting, Estimated PCD: 2029-09-30
Clinical trial
A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical CenterStatus: Recruiting, Estimated PCD: 2024-12-28
Clinical trial
Recurrence Free Survival After Curative Resection of Non-small Cell Lung Cancer Between Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia: a Multicenter, Randomized, Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2028-12-31
Clinical trial
A Phase II, Open-label, Single-arm, Multicenter, Efficacy and Safety of 80mg Osimertinib in Patients With Leptomeningeal Metastases(LM) Associated With EGFR Mutation-positive Non-small Cell Lung Cancer(NSCLC)Status: Completed, Estimated PCD: 2023-10-25
Clinical trial
Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant CyclophosphamideStatus: Recruiting, Estimated PCD: 2023-07-05
Clinical trial
Evaluate the Safety and Potential Efficacy of Human Wharton's Jelly-derived Mesenchymal Stem Cells (EN001) in Patients With Charcot-Marie-Tooth Disease Type 1EStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
Modulating Surgery-Induced Blood-Brain Barrier Disruption in Elderly: Impact of Dexmedetomidine and Lidocaine, a Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Open Label Trial of Maintenance Enzalutamide in CRPCStatus: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Phase II Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) for Actionable EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Effect of Dexmedetomidine Infusion, Lidocaine Infusion, and Intrathecal Morphine Injection on Biomarker for Perioperative Stress and Immune Response, and Cancer Progression and Metastasis in Colorectal Cancer SurgeryStatus: Completed, Estimated PCD: 2023-07-05
Clinical trial
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Comparison of Dual Therapy of Dexamethasone and Palonosetron and Triple Therapy of Dexamethasone, Palonosetron, Fosaprepitant for Postoperative Nausea and Vomiting Prevention: A Randomized Controlled TrialStatus: , Estimated PCD: 2024-03-30
Clinical trial
Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX)Status: Recruiting, Estimated PCD: 2019-07-08
Clinical trial
A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) AmplificationStatus: Completed, Estimated PCD: 2018-09-08
Clinical trial
Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)Status: Active (not recruiting), Estimated PCD: 2023-03-11
Clinical trial
Total Intravenous Anesthesia for Rigid Bronchoscopy - Remimazolam Versus Propofol: a Prospective Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
Peri-tREatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index Measured by Cardiac maGnetic rEsonance Imaging in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary InterventionStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Antiplatelet Agents in Patients With Intermediate Coronary Artery Stenosis and Negative Fractional Flow ReserveStatus: Active (not recruiting), Estimated PCD: 2020-12-31
Clinical trial
A Phase II, Open Label, Randomized Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) in Other Lobes After Curative Resection for Actionable EGFR Mutation-positive Stage I Lung AdenocarcinomaStatus: Withdrawn, Estimated PCD: 2020-10-07
Clinical trial
A Phase II, Open-label, Single-arm, Multi-center Clinical Trial of Rivoceranib in Patients With Metastatic Thymic Epithelial TumorStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Aspirin and a Potent P2Y12 Inhibitor Versus Aspirin and Clopidogrel Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention for Complex Lesion Treatment (SMART-ATTEMPT)Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal AdenocarcinomaStatus: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Randomized, Single-Blind, Investigator Initiative Trial Study of Remimazolam Versus Midazolam for Sedation in Diagnostic Upper Gastrointestinal EndoscopyStatus: Not yet recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized Multicenter Noninferiority Trial Comparing Chemoradiotherapy Versus Esophagectomy After Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma (ASSURE)Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial CancerStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Effects of PPI on GI Bleeding and Cardiovascular Outcomes Among Post-MI Patients Taking DAPTStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Effect of Intensive Nutritional Support on Functional Recovery in Subacute Stroke PatientStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination Versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM (DECISION-CAL)Status: Not yet recruiting, Estimated PCD: 2029-06-30
Clinical trial
Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic AnalysisStatus: Completed, Estimated PCD: 2021-12-01
Abstract
Relationship between tumor microenvironment (TME)-based histomic TGFβ signature (TGFBs), stromal fibroblast recruitment, and exclusion of immune cells as immunotherapy resistance mechanisms.Org: Lunit Inc., Stanford University School of Medicine, Samsung Medical Center, Department of Pathology, Chonnam National University Hospital, Department of Pathology, Seoul National University Bundang Hospital,
Abstract
Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Chonnam National University Medical School and Hwasun Hospital,
Abstract
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.Org: Memorial Sloan Kettering Cancer Center, Stanford University Medical Center, Stanford, CA, Seoul National University Bundang Hospital, START Midwest, Grand Rapids, MI, Samsung Medical Center,
Abstract
Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.Org: Affimed Inc., Samsung Medical Center, INCLIVA, Biomedical Research Institute, Vall d'Hebron Institute of Oncology, Affimed,
Abstract
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Kyung Hee University Hospital,
Abstract
Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study.Org: Samsung Medical Center, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, University Hospital Erlangen, Comprehensive Cancer Center (CCC) Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg,
Abstract
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Humanitas University, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki University Hospital Comprehensive Cancer Center, Semmelweis University,
Abstract
STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.Org: Moffitt Cancer Center, Samsung Medical Center, Sarah Cannon Research Institute/Tennessee Oncology, Gilead Sciences, Inc., Arcus Biosciences,
Abstract
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.Org: Genome Insight Inc., Samsung Medical Center, Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Research Institute for Future Medicine,
Abstract
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.Org: Yonsei Cancer Center, Yonsei University Health System, Maria Sklodowska-Curie National Research Institute of Oncology, James Lind Cancer Research Center, Temuco, Chile, Harbin Medical University Cancer Hospital, Asan Medical Center,
Abstract
Comprehensive profiling of mutational signatures and machine learning and subtypes of homologous recombination deficiency.Org: Genome Insight Inc., Research Institute for Future Medicine, Division of Breast Surgery, Division of Breast and Endocrine Surgery, Samsung Medical Center,
Abstract
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vanderbilt University Medical Center, Jewish General Hospital Stroll Cancer Prevention Centre, Queensland Health, Ramón y Cajal University Hospital,
Abstract
BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis.Org: Trinity St. James’s Cancer Institute, Cross Cancer Institute, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University Health System, Princess Margaret Cancer Centre,
Abstract
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, University of Colorado Health Science Center, University of California Los Angeles,
Abstract
Artificial intelligence (AI) –powered spatial analysis of tumor-infiltrating lymphocytes (TILs) for prediction of prognosis in resectable pancreatic adenocarcinoma (PDAC).Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center,
Abstract
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).Org: Yonsei University College of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea University College of Medicine, Seoul National University Bundang Hospital,
Abstract
Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments.Org: Gangnam Severance Hospital, Yonesi University College of Medicine, Seoul National University Hospital, Asan Medical Center, Center for Breast Cancer,
Abstract
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Org: MD Anderson Cancer Center, Brown University - Lifespan Cancer Institute, Hospital de Clinicas de Porto Alegre, Samsung Medical Center, Pusan National University Hospital,
Abstract
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).Org: Hadassah Medical Center, Ankara University School of Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Institut Català d'Oncologia Hospitalet, Samsung Medical Center,
Abstract
A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Samsung Medical Center, Seoul, South Korea, Samsung Medical Center, Gangnam-Gu, South Korea,
Abstract
Immune checkpoint inhibitors use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.Org: Yongin Severance Hospital, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine, Samsung Medical Center, Samsung Medical Hospital,
Abstract
A first-in-human, open-label, dose escalation and expansion study of orally administered NX-019 in patients with advanced EGFR mutant cancer.Org: NEXT Oncology - Virginia Cancer Specialists, Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul National University College of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Seoul National University Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
A phase 1a/b study of BR101801, a PI3K γ/δ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.Org: Boryung Corporation, Samsung Medical Center, Seoul National University Cancer Research Institute, Seoul, Republic of Korea, Seoul National University Hospital, Asan Medical Center,
Abstract
Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25).Org: Gangnam Severance Hospital, Yonesi University College of Medicine, Gangnam-Gu, Nacuity Pharmaceuticals, Korea United Pharmaceuticals Inc.,
Abstract
Long-term quality of life and nutritional results of stomach-preserving surgery after sentinel node evaluation in patients with early gastric cancer: A multicenter, randomized phase 3 trial (SENORITA).Org: National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Gyeonggi-do, South Korea, Korea, Republic of (South),
Abstract
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Medicine, Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Harvard Medical School, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Performance validation of an artificial intelligence-powered PD-L1 combined positive score analyzer in six cancer types.Org: Lunit Inc., Samsung Medical Center, Ajou University School of Medicine, Chonnam National University Hospital,
Abstract
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.Org: SAIHST, Sungkyunkwan University of Medicine, Samsung Medical Center,
Abstract
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.Org: Lung Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Sarah Cannon Research Institute at HealthONE, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort.Org: INCLIVA-Biomedical Research Institute, Biomedical Research Institute INCLIVA, Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, University of Valencia, Affimed Inc.,
Abstract
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.Org: University of Colorado Cancer Center, Sendai Kousei Hospital, Fujita Health University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,
Abstract
ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.Org: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Columbia University Irving Medical Center, New York, NY, USA, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Samsung Medical Center,
Abstract
Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer.Org: Eutilex Co., Ltd., Samsung Medical Center, Sungkyunkwan University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Advanced deep-learning algorithm for multi-cancer detection using cf-WGS.Org: GC Genome, Yongin, South Korea, Able Analytics, AbleAnalytics, Asan Medical Center, University of Ulsan College of Medicine,
Abstract
Sustained prognostic impact of primary tumor characteristics on long-term (overall) survival after distant metastasis in young ER+ HER2- breast cancer.Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Dongtan Sacred Heart Hospital, Hallym University, Seoul National University College of Medicine, Samsung Medical Center,
Abstract
Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Section of Hematology & Oncology, University of Chicago Medical Center, Dana-Farber Cancer Institute, Department of Internal Medicine, Seoul National University Bundang Hospital,
Abstract
Deep learning-based ensemble model using hematoxylin and eosin (H&E) whole slide images (WSIs) for the prediction of MET mutations in non-small cell lung cancer (NSCLC).Org: Samsung Medical Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, Sungkyunkwan University School of Medicine, Samsung Medical Hospital,
Abstract
Whole genome sequencing for more accurate TMB and mutational signatures in common cancers.Org: Genome Insight Inc., Ajou University School of Medicine, Genome Insight, San Diego, CA, Seoul National University College of Medicine, Seoul National University Hospital,
Abstract
Immune phenotype-driven treatment outcome of IO-only versus chemo-IO in PD-L1-high, first-line, advanced non-small cell lung cancer (NSCLC).Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Samsung Medical Center, Gangnam-Gu, South Korea, Samsung Medical Center, Seoul, South Korea,
Abstract
Clinical outcomes of extramammary Paget’s disease in Korea: A multicenter, retrospective study.Org: Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea, Asan Medical Center, Seoul National University Hospital, Samsung Medical Center, Seoul St. Mary's Hospital,
Abstract
Transcriptomic subtype, TP53 mutation status, and APOBEC mutation signature in early-stage EGFR-mutant non-small-cell lung cancer.Org: Samsung Medical Center, Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea, Samsung Medical Hospital, Sungkyunkwan University School of Medicine,
Abstract
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).Org: Centre François Baclesse, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Centre Léon Bérard, Hospital Universitario Reina Sofia de Cordoba, GEICO,
Abstract
Clinical trial versus standard of care in EGFR-wild type and ALK- negative lung adenocarcinoma: A propensity-matched analysis.Org: Samsung Medical Center, Samsung Medical Center, Gangnam-Gu, South Korea, Samsung Medical Center, Seoul, South Korea, Department of Internal Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Samsung Medical Hospital, Seoul, Korea, Republic of (South),
Abstract
ASSOCIATION BETWEEN ANEMIA AND HYPERURICEMIA: KOREAN NATIONAL HEALTH AND NUTRITION SURVEY 2016Org: Samsung Medical Center, National Medical Center, Bundang Jesaeng General Hospital,